D-Glutamate

D-Glutamate

SCHEMBL671944

N.N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.95
GRM6 O15303 2/20 0.95
GRM7 Q14831 2/20 0.95
GRM4 Q14833 2/20 0.95
GSR P00390 2/20 0.95
GRIN2D O15399 1/20 0.95
GRIN3B O60391 1/20 0.95
CYP1A2 P05177 1/20 0.95
GRIK1 P39086 1/20 0.95
GRM5 P41594 1/20 0.95
GRIA1 P42261 1/20 0.95
GRIA2 P42262 1/20 0.95
GRIA3 P42263 1/20 0.95
SLC1A3 P43003 1/20 0.95
SLC1A2 P43004 1/20 0.95
SLC1A1 P43005 1/20 0.95
GRIA4 P48058 1/20 0.95
GRIN1 Q05586 1/20 0.95
GRIN2A Q12879 1/20 0.95
GRIK2 Q13002 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL648217 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL978651 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL648218 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL671942 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL28166198 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL27549484 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL28006261 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL30525806 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL28091015 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL28166196 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250354183-A1 METHOD FOR PRODUCING L-GLUTAMIC ACID AJINOMOTO CO., INC. (JP) 2025-11-20 US claimed
EP-4567123-A2 METHOD FOR PRODUCING L-AMINO ACID AJINOMOTO CO., INC. (JP) 2025-06-11 EP claimed
WO-2024162450-A1 METHOD FOR PRODUCING L-GLUTAMIC ACID 味の素株式会社 2024-08-08 WO claimed
US-20240117393-A1 METHOD FOR PRODUCING L-AMINO ACID AJINOMOTO CO., INC. (JP) 2024-04-11 US claimed
EP-4345166-A2 METHOD FOR PRODUCING L-AMINO ACID AJINOMOTO CO., INC. (JP) 2024-04-03 EP claimed
US-20230416793-A1 METHOD OF PRODUCING L-AMINO ACID AJINOMOTO CO., INC. (JP) 2023-12-28 US claimed
EP-4239070-A1 METHOD OF PRODUCING L-AMINO ACID AJINOMOTO CO., INC. (JP) 2023-09-06 EP claimed
CN-107034250-B Process for producing glutamic acid-containing L-amino acid 味之素株式会社 2021-09-21 CN claimed
US-9789720-B2 Image forming method, image forming apparatus, and recorded matter RICOH COMPANY, LTD. (JP) 2017-10-17 US claimed
EP-2872338-B1 IMAGE FORMING METHOD AND IMAGE FORMING APPARATUS RICOH CO LTD (JP) 2017-03-15 EP claimed
US-8980408-B2 Liquid composition, recording method, and recorded matter RICOH COMPANY, LTD. (JP) 2015-03-17 US claimed
US-20130143008-A1 LIQUID COMPOSITION, RECORDING METHOD, AND RECORDED MATTER RICOH COMPANY, LTD. (JP) 2013-06-06 US claimed
JP-60192570-A None JP disclosed
JP-60153773-A None JP disclosed
CN-122095475-A Power unit comprising different droplets separated by amphiphilic membranes 2026-05-26 CN disclosed
US-20260139148-A1 INKJET TREATMENT SOLUTION, AND INKJET PRINTING DEVICE KYOCERA CORP (JP) 2026-05-21 US disclosed
JP-2004261098-A FLAVOR-ENHANCING COMPOSITION SANEI GEN FFI INC 2004-09-24 JP disclosed
US-4956471-A Process for isolating and purifying amino acids AJINOMOTO COMPANY, INC. (JP) 1990-09-11 US disclosed
JP-S60192570-A PREPARATION OF SEASONING OR FOOD AJINOMOTO CO INC 1985-10-01 JP disclosed
JP-S60153773-A ACIDIC SEASONING OR SEASONED ACIDIC FOOD AJINOMOTO CO INC 1985-08-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139148-A1 INKJET TREATMENT SOLUTION, AND INKJET PRINTING DEVICE SFRP1, FLOT1, NLRP3 GRM8 4837/4885GRM6 4879/4885GRM7 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.